TY - JOUR
T1 - Elevated serum adipocyte fatty acid-binding protein concentrations are independently associated with renal dysfunction in patients with stable angina pectoris
AU - Iwamoto, Mutsumi
AU - Miyoshi, Toru
AU - Doi, Masayuki
AU - Takeda, Ko
AU - Kajiya, Masahito
AU - Nosaka, Kazumasa
AU - Nakayama, Rie
AU - Hirohata, Satoshi
AU - Usui, Shinichi
AU - Kusachi, Shozo
AU - Sakane, Kosuke
AU - Nakamura, Kazuhfumi
AU - Ito, Hiroshi
PY - 2012/3/21
Y1 - 2012/3/21
N2 - Background: Chronic kidney disease (CKD) is associated with cardiovascular events. Adipocyte fatty acid-binding protein (A-FABP) plays an important role in atherosclerosis. We investigated whether plasma A-FABP is involved in renal function in patients with stable angina pectoris.Methods: A total of 221 patients with significant coronary artery stenosis were enrolled after coronary angiography. CKD was defined as an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m 2. The severity of coronary stenosis was assessed using a modified Gensini score and coronary angiography. Serum A-FABP levels were determined by enzyme-linked immunosorbent assay.Results: Serum A-FABP levels were significantly correlated with both eGFR (r = -0.41, p < 0.01) and the severity of coronary artery stenosis (r = 0.16, p = 0.02), and these relationships remained significant after adjusting for confounding factors. The prevalence of CKD and multi-vessel disease was significantly higher among patients with serum A-FABP levels above the median value of 20.3 ng/ml than among patients with serum A-FABP levels below the median value (57% vs. 27%, p < 0.01 and 64% vs. 48%, p = 0.02, respectively). Multivariate analysis revealed that the presence of three-vessel disease in comparison with single-vessel disease was independently associated with the higher A-FABP (per doubling) (odds ratio; 2.26, 95% confidential interval; 1.28-3.98, p < 0.01) and tended to be associated with the lower eGFR (p = 0.06).Conclusion: Serum A-FABP may have a significant role in the interplay between renal dysfunction and coronary atherosclerosis.
AB - Background: Chronic kidney disease (CKD) is associated with cardiovascular events. Adipocyte fatty acid-binding protein (A-FABP) plays an important role in atherosclerosis. We investigated whether plasma A-FABP is involved in renal function in patients with stable angina pectoris.Methods: A total of 221 patients with significant coronary artery stenosis were enrolled after coronary angiography. CKD was defined as an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m 2. The severity of coronary stenosis was assessed using a modified Gensini score and coronary angiography. Serum A-FABP levels were determined by enzyme-linked immunosorbent assay.Results: Serum A-FABP levels were significantly correlated with both eGFR (r = -0.41, p < 0.01) and the severity of coronary artery stenosis (r = 0.16, p = 0.02), and these relationships remained significant after adjusting for confounding factors. The prevalence of CKD and multi-vessel disease was significantly higher among patients with serum A-FABP levels above the median value of 20.3 ng/ml than among patients with serum A-FABP levels below the median value (57% vs. 27%, p < 0.01 and 64% vs. 48%, p = 0.02, respectively). Multivariate analysis revealed that the presence of three-vessel disease in comparison with single-vessel disease was independently associated with the higher A-FABP (per doubling) (odds ratio; 2.26, 95% confidential interval; 1.28-3.98, p < 0.01) and tended to be associated with the lower eGFR (p = 0.06).Conclusion: Serum A-FABP may have a significant role in the interplay between renal dysfunction and coronary atherosclerosis.
KW - Adipocyte
KW - Coronary artery disease
KW - Fatty acid-binding protein
KW - Renal dysfunction
UR - http://www.scopus.com/inward/record.url?scp=84858610086&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858610086&partnerID=8YFLogxK
U2 - 10.1186/1475-2840-11-26
DO - 10.1186/1475-2840-11-26
M3 - Article
C2 - 22433902
AN - SCOPUS:84858610086
VL - 11
JO - Cardiovascular Diabetology
JF - Cardiovascular Diabetology
SN - 1475-2840
M1 - 26
ER -